Evidence map›Paper›PMID 35212924›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer.

M Loi, G Salvatore, M Sottili, L Calosi, I Desideri, C Becherini, V Salvestrini, L P Ciccone, G Stocchi, I Meattini and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

M LoiRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy. mauro.loi@unifi.it.ORCID http://orcid.org/0000-0002-0360-3275
G SalvatoreRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
M SottiliRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
L CalosiDepartment of Experimental and Clinical Medicine, Section of Anatomy and Histology, Research Unit of Histology an Embryology, University of Florence, Florence, Italy.
I DesideriRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
C BecheriniRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
V SalvestriniRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
L P CicconeRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
G StocchiRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
I MeattiniRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
G FrancoliniRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
M MangoniRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
L LiviRadiotherapy Department, University of Florence, 3, Largo Brambilla, 50124, Florence, Italy.
University of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTumor-associated macrophages (TAM) may participate to antitumor activity of anti-HER2-targeted therapies (Pertuzumab, Trastuzumab) in breast cancers harbouring HER-2 overexpression through antibody-dependent phagocytosis. Additive antitumor effect of concurrent cytotoxic chemotherapies, including Paclitaxel, may be counterbalanced by alteration in TAM infiltrate. The aim of this study is to evaluate the role of TAM in tumor response to anti-HER2-targeted therapies and chemotherapy in an experimental model of HER2-amplified breast cancer.

methodsA xenograft mouse model was built by subcutaneous injection of the SKBR-3 human HER2-amplified breast cancer cell line in Hu-CD34+ mice. Animals were randomized to receive weekly administration of Cremophor (control), Trastuzumab+Pertuzumab (TP), and Paclitaxel+Trastuzumab+Pertuzumab (PTP) with or without macrophage depletion with clodronate (C). At week 4, mice were euthanised and tumors were harvested for immunohistochemical analysis of TAM infiltration (RBP-J CD163 and CD68 for M1, M2, and overall TAM, respectively).

resultsTumor size was significantly lower in mice treated with TP, PTP, and PTP+C as compared to control, while no meaningful difference was observed in the TP+C arm. Analysis of TAM infiltrate showed significantly lower CD68 and CD163 expression in PTP, TP+C, and PTP+C as compared to TP and control arm. RBP-J expression was significantly decreased in mice treated with clodronate depletion.

conclusionsActivity of TP is modulated by TAM infiltrate, that is inhibited by concurrent administration of Paclitaxel. To enhance the effect of anti-HER2-targeted therapies and minimize chemotherapy-related side effects, modulation of TAM should be considered in novel therapeutic combinations.

Indexed as

Antineoplastic AgentsBreast NeoplasmsAnimalsCell Line, TumorClodronic AcidErb-b2 Receptor Tyrosine KinasesFemaleHumansMicePaclitaxelTrastuzumabTumor-Associated MacrophagesAntineoplastic AgentsClodronic AcidErb-b2 Receptor Tyrosine KinasesPaclitaxelTrastuzumabBreast cancerHu-CD34 + micePertuzumabTrastuzumabTumor-associated macrophages (TAM)

Identifiers

PMID35212924
OpenAlexW4214515234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.